Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

WFNOS Magazine

The inaugural issue of the official publication of the World Federation of Neuro-Oncology Societies is ...

Read Full Story

Neuro-Oncology Review Course at SNO

November 16, 2016. Register in conjunction with the SNO Annual Meeting

Read Full Story

CNS Anticancer Drug Discovery and Development Conference

Register Now!

Read Full Story
View All News

October
12

EANO 2016

Read Full Story

October
22

18th Annual Brain Tumor Update and 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine

Read Full Story

November
16

2nd CNS Anticancer Drug Discovery/Development Conference

Read Full Story

Dana Farber Cancer Institute

Dana Farber Cancer Institute
Center for Neuro-Oncology
44 Binney St., Shields Warren G430D
Boston, MA  02115
USA

Patrick Y. Wen, M.D.

Contact:
Vida Tafoya, Administrative Specialist
vida_tafoya@dfci.harvard.edu
617-632-6158
 

Research Categories:
My research is directed towards the development of new therapies for brain tumors and leptomeningeal metastases using especially tageted molecular agents and inhibitors of angiogenesis. I am also interested in the neurologic complications in cancer patients.

Research Interest/Projects:

The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines.

A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.